Schroder Adveq logo

Schroder Adveq

Europe, Zurich, Switzerland, Zürich

Description

Schroder Adveq, now fully integrated into Schroders Capital, stands as a prominent global private equity investor with a long-standing track record. Originally founded as Adveq in 1997, the firm was acquired by Schroders in 2016, significantly bolstering Schroders' private assets capabilities. As part of Schroders Capital, the entity now manages a substantial portfolio, with over $80 billion in private assets under management as of December 31, 2023. This integration has allowed Schroder Adveq to leverage a broader platform and deeper resources while maintaining its specialized focus on private equity.

The firm's investment strategy is comprehensive, spanning primaries, secondaries, and co-investments across a global mandate. In primaries, they commit capital to a diverse range of private equity funds, including venture capital, growth equity, and small to mid-market buyouts. Their secondary activities involve acquiring existing limited partnership interests, providing liquidity solutions to investors. Crucially, their co-investment program enables direct participation in portfolio companies alongside their fund managers, offering direct exposure to promising businesses. This diversified approach allows them to construct robust portfolios resilient to market fluctuations and capitalize on opportunities across various stages and sectors.

Schroder Adveq, through Schroders Capital, emphasizes a disciplined investment process characterized by rigorous due diligence and a long-term partnership approach. They seek to collaborate with top-tier general partners globally, leveraging their extensive network and deep market insights. The firm's commitment to building diversified portfolios is evident in its strategy to spread risk across geographies, industries, and investment styles. Since its inception, the private equity division has raised over 100 private equity funds, underscoring its significant experience and consistent capital deployment in the asset class.

While Schroder Adveq primarily operates as a fund-of-funds, their active co-investment strategy means they do participate directly in company funding rounds. These co-investments typically range from significant growth capital injections to substantial contributions in buyout transactions. Based on the scale of their overall operations and the types of deals they participate in, their typical direct co-investment check sizes are estimated to fall between $2 million and $50 million, reflecting their involvement in various stages from late-stage venture to mid-market buyouts.

Investor Profile

Schroder Adveq has backed more than 34 startups, with 0 new investments in the last 12 months alone. The firm has led 4 rounds, about 12% of its total and boasts 6 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series C, Series A rounds (top funding stages).
  • Majority of deals are located in Switzerland, United States, India.
  • Strong thematic focus on Biotechnology, Health Care, Therapeutics.
  • Typical check size: $2M – $50M.

Stage Focus

  • Series B (32%)
  • Series C (24%)
  • Series A (18%)
  • Seed (15%)
  • Series E (3%)
  • Series I (3%)
  • Secondary Market (3%)
  • Series Unknown (3%)

Country Focus

  • Switzerland (50%)
  • United States (26%)
  • India (15%)
  • United Kingdom (6%)
  • China (3%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Medical
  • Life Science
  • Biopharma
  • Medical Device
  • E-commerce
  • Supply Chain Management
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Schroder Adveq frequently co-invest with?

BioMedPartners
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 6
S-Cubed Capital
North America, California, United States, Menlo Park
Co-Investments: 3
Eventide
North America, Massachusetts, United States, Boston
Co-Investments: 4
VI Partners
Europe, Schwyz, Switzerland, Altendorf
Co-Investments: 6
Third Rock Ventures
North America, Massachusetts, United States, Boston
Co-Investments: 5
Casdin Capital
North America, New York, United States, New York
Co-Investments: 4
HTGF | High-Tech Gruenderfonds
Europe, Nordrhein-Westfalen, Germany, Bonn
Co-Investments: 5
BB
Europe, Zug, Switzerland, Zug
Co-Investments: 6
The Column Group
North America, California, United States, San Francisco
Co-Investments: 3
redalpine
Europe, Zurich, Switzerland, Zürich
Co-Investments: 6

Which angels does Schroder Adveq often collaborate with?

DV
Europe, Basel-Stadt, Switzerland, Basel
Shared Deals: 1
BR
Europe, Zurich, Switzerland
Shared Deals: 1
RA
Europe, Basel-Stadt, Switzerland, Basel
Shared Deals: 1

What are some of recent deals done by Schroder Adveq?

Bizongo

Mumbai, Maharashtra, India

Bizongo develops tech-enabled B2B platforms for raw material procurement, vendor digitization, supply chain financing, and ESG scorecards.

ApparelB2BE-CommercePackaging ServicesSupply Chain Management
Series EOct 4, 2023
Amount Raised: $49,978,954
Lenskart

Gurgaon, Haryana, India

Lenskart is an online optical platform that sells prescription eyewear, branded contact lenses, sunglasses, and accessories.

DeliveryE-CommerceEyewearFashionShopping
Series IJun 9, 2022
Amount Raised: $28,257,898
ImmunOs Therapeutics

Schlieren, Zurich, Switzerland

ImmunOs Therapeutics is a clinical-stage biotechnology company.

BiotechnologyHealth CarePharmaceutical
Series BJun 7, 2022
Amount Raised: $72,923,803
HAYA Therapeutics

Lausanne, Vaud, Switzerland

HAYA Therapeutics is a biopharmaceutical company that specializes in treating heart failure diseases.

BiopharmaBiotechnologyHealth CareMedical
SeedFeb 9, 2022
Amount Raised: $5,000,000
LEAP India

Kandivli, Maharashtra, India

LEAP INDIA is a supply chain solutions company.

Management ConsultingSupply Chain ManagementTransportation
Secondary MarketAug 4, 2021
Amount Raised: $34,000,000
Alentis Therapeutics

Basel, Basel-Stadt, Switzerland

ALENTIS Therapeutics is a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer.

BiotechnologyTherapeutics
Series BJun 15, 2021
Amount Raised: $66,763,102
Tessian

London, England, United Kingdom

Tessian creates a Human Layer Security that helps people work without security disruptions getting in the way.

Artificial Intelligence (AI)Cyber SecurityEmailMachine LearningProfessional Services
Series CMay 25, 2021
Amount Raised: $65,000,000
HAYA Therapeutics

Lausanne, Vaud, Switzerland

HAYA Therapeutics is a biopharmaceutical company that specializes in treating heart failure diseases.

BiopharmaBiotechnologyHealth CareMedical
SeedMay 20, 2021
Amount Raised: $20,053,856
HAYA Therapeutics

Lausanne, Vaud, Switzerland

HAYA Therapeutics is a biopharmaceutical company that specializes in treating heart failure diseases.

BiopharmaBiotechnologyHealth CareMedical
SeedMay 5, 2021
Amount Raised: $18,000,000
Bizongo

Mumbai, Maharashtra, India

Bizongo develops tech-enabled B2B platforms for raw material procurement, vendor digitization, supply chain financing, and ESG scorecards.

ApparelB2BE-CommercePackaging ServicesSupply Chain Management
Series CApr 26, 2021
Amount Raised: $51,000,000